IFN ‐λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy
Immunology · 2025
DOI: 10.1111/imm.13954 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, 2025. Verfasst von Benfeng Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Molecular Medicine, Jining Medical University, Jining, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Interferons, Inflammation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 142 Literaturangaben. Gefördert von: Jining Medical University Training Program of Innovation and Entrepreneurship for Undergraduates, National Natural Science Foundation of China, Research Fund for Academician Lin He New Medicine.
Abstract (Originalsprache)
Type III interferons (IFN‐λ), which include IFN‐λ1 (or interleukin [IL]‐29), IFN‐λ2 (IL‐28A), IFN‐λ3 (IL‐28B) and IFN‐λ4, exert their effects through a unique receptor complex composed of interferon lambda receptor 1 (IFNLR1) and IL‐10 receptor subunit beta (IL‐10R2). Studies have highlighted their critical role in modulating immune response, particularly in the context of autoimmune diseases, viral infections and cancer. Unlike type I IFNs, which are broadly expressed, IFN‐λ displays a more tissue‐specific expression pattern, predominantly acting on epithelial cells and certain immune cell types, such as neutrophils and B cells. This specificity allows IFN‐λ to play a pivotal role in mucosal immunity, particularly at barrier sites, such as the respiratory and gastrointestinal tracts. Emerging evidence suggests that IFN‐λ has a dual role in both enhancing antiviral immunity and regulating inflammation, thus offering a promising therapeutic strategy for diseases like systemic lupus erythematosus, rheumatoid arthritis, asthma and various cancers. However, the precise mechanisms by which IFN‐λ influence immune modulation and disease progression remain an area of active investigation. This review aims to provide an overview of the structure, function and signalling pathways of IFN‐λ, exploring their role in immune‐related diseases and discussing potential avenues for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.
- Jining Key Laboratory of Immunology, Jining Medical University, Jining, China.
- School of Basic Medicine, Shandong First Medical University, Jinan, China.
ORCID-Profile: Junfeng Zhang
Förderung
- Jining Medical University Training Program of Innovation and Entrepreneurship for Undergraduates
- National Natural Science Foundation of China
- Research Fund for Academician Lin He New Medicine
- Doctoral Startup Fund of Jining Medical University
Zitieren
APA
Tang, B., Liu, Z., Xiong, H., Zhang, J., & Dai, J. (2025). IFN ‐λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy. Immunology. https://doi.org/10.1111/imm.13954
Vancouver
Tang B, Liu Z, Xiong H, Zhang J, Dai J. IFN ‐λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy. Immunology. 2025. doi:10.1111/imm.13954
BibTeX
@article{Tang2025,
author = {Tang, Benfeng and Liu, Zhihong and Xiong, Huabao and Zhang, Junfeng and Dai, Jun},
title = {IFN ‐λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy},
journal = {Immunology},
year = {2025},
doi = {10.1111/imm.13954}
}
EUVIMED